Efthimiou Petros, Markenson Joseph A
Hospital for Special Surgery, Weill Medical College of Cornell University, New York, New York 10021, USA.
South Med J. 2005 Feb;98(2):192-204. doi: 10.1097/01.SMJ.0000153119.37032.8B.
A new era in the treatment of immune-mediated inflammatory disorders has begun with the clinical availability of anticytokine therapy. Biological agents that are currently available include 3 agents that decrease the activity of tumor necrosis factor-alpha (infliximab, adalimumab, etanercept) and an interleukin-1 receptor antagonist (anakinra), with many more in development. Those extraordinarily effective medications are an important addition to our therapeutic armamentarium, and, although originally developed for rheumatoid arthritis and Crohn disease, have been found to be efficacious in the treatment of seronegative spondyloarthropathies (psoriatic arthritis, ankylosing spondylitis) and juvenile rheumatoid arthritis. Their role is currently being defined in other autoimmune disorders such as uveitis, sarcoidosis, interstitial lung disease, vasculitis, inflammatory myopathies, graft-versus-host disease, and Sjögren syndrome.
抗细胞因子疗法在临床上的应用开启了免疫介导性炎症疾病治疗的新纪元。目前可用的生物制剂包括3种可降低肿瘤坏死因子-α活性的药物（英夫利昔单抗、阿达木单抗、依那西普）和1种白细胞介素-1受体拮抗剂（阿那白滞素），还有更多药物正在研发中。这些极其有效的药物是我们治疗手段的重要补充，尽管最初是为类风湿关节炎和克罗恩病开发的，但已发现它们对血清阴性脊柱关节病（银屑病关节炎、强直性脊柱炎）和青少年类风湿关节炎的治疗有效。它们在其他自身免疫性疾病如葡萄膜炎、结节病、间质性肺病、血管炎、炎性肌病、移植物抗宿主病和干燥综合征中的作用目前正在明确。
Zotero 插件